These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 29086643)

  • 1. Exploring the Obstacles to Implementing Economic Mechanisms to Stimulate Antibiotic Research and Development: A Multi-Actor and System-Level Analysis.
    Baraldi E; Ciabuschi F; Leach R; Morel CM; Waluszewski A
    Am J Law Med; 2016 May; 42(2-3):451-486. PubMed ID: 29086643
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Grant Framework as a Push Incentive to Stimulate Research and Development of New Antibiotics.
    Savic M; Årdal C
    J Law Med Ethics; 2018 Jun; 46(1_suppl):9-24. PubMed ID: 30146963
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incentivising innovation in antibiotic drug discovery and development: progress, challenges and next steps.
    Simpkin VL; Renwick MJ; Kelly R; Mossialos E
    J Antibiot (Tokyo); 2017 Dec; 70(12):1087-1096. PubMed ID: 29089600
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improving antibiotic markets for long-term sustainability.
    Kesselheim AS; Outterson K
    Yale J Health Policy Law Ethics; 2011; 11(1):101-67. PubMed ID: 21381513
    [No Abstract]   [Full Text] [Related]  

  • 5. Public funding of clinical-stage antibiotic development in the United States and European Union.
    Eichberg MJ
    Health Secur; 2015; 13(3):156-65. PubMed ID: 26042859
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Economic Incentives for Antibacterial Drug Development: Literature Review and Considerations From the Transatlantic Task Force on Antimicrobial Resistance.
    Sciarretta K; Røttingen JA; Opalska A; Van Hengel AJ; Larsen J
    Clin Infect Dis; 2016 Dec; 63(11):1470-1474. PubMed ID: 27578820
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Insights into early stage of antibiotic development in small- and medium-sized enterprises: a survey of targets, costs, and durations.
    Årdal C; Baraldi E; Theuretzbacher U; Outterson K; Plahte J; Ciabuschi F; Røttingen JA
    J Pharm Policy Pract; 2018; 11():8. PubMed ID: 29632669
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systems, not pills: The options market for antibiotics seeks to rejuvenate the antibiotic pipeline.
    Brogan DM; Mossialos E
    Soc Sci Med; 2016 Feb; 151():167-72. PubMed ID: 26808335
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Encouraging Sustainable Use of Antibiotics: A Commentary on the DRIVE-AB Recommended Innovation Incentives.
    Morel CM; Edwards SE
    J Law Med Ethics; 2018 Jun; 46(1_suppl):75-80. PubMed ID: 30146962
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Past, Present, and Future of Antibacterial Economics: Increasing Bacterial Resistance, Limited Antibiotic Pipeline, and Societal Implications.
    Luepke KH; Suda KJ; Boucher H; Russo RL; Bonney MW; Hunt TD; Mohr JF
    Pharmacotherapy; 2017 Jan; 37(1):71-84. PubMed ID: 27859453
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Countries mull over incentives for developing antibiotics.
    Anderson T
    Lancet; 2016 May; 387(10031):1894-5. PubMed ID: 27203638
    [No Abstract]   [Full Text] [Related]  

  • 12. Stimulating Research and Development of New Antibiotics While Ensuring Sustainable Use and Access: Further Insights from the DRIVE-AB Project and Others.
    Bettiol E; Hackett J; Harbarth S
    J Law Med Ethics; 2018 Jun; 46(1_suppl):5-8. PubMed ID: 30146955
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of economic, regulatory, and patent policies on innovation in cancer chemoprevention.
    Grabowski HG; Moe JL
    Cancer Prev Res (Phila); 2008 Jul; 1(2):84-90. PubMed ID: 19138940
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Repairing the broken market for antibiotic innovation.
    Outterson K; Powers JH; Daniel GW; McClellan MB
    Health Aff (Millwood); 2015 Feb; 34(2):277-85. PubMed ID: 25646108
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Time for a change in how new antibiotics are reimbursed: Development of an insurance framework for funding new antibiotics based on a policy of risk mitigation.
    Towse A; Hoyle CK; Goodall J; Hirsch M; Mestre-Ferrandiz J; Rex JH
    Health Policy; 2017 Oct; 121(10):1025-1030. PubMed ID: 28888660
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulatory Incentives for Antibiotic Drug Development: A Review of Recent Proposals.
    Sinha MS; Kesselheim AS
    Bioorg Med Chem; 2016 Dec; 24(24):6446-6451. PubMed ID: 27591793
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The roles of patents and research and development incentives in biopharmaceutical innovation.
    Grabowski HG; DiMasi JA; Long G
    Health Aff (Millwood); 2015 Feb; 34(2):302-10. PubMed ID: 25646111
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibiotic reimbursement in a model delinked from sales: a benchmark-based worldwide approach.
    Rex JH; Outterson K
    Lancet Infect Dis; 2016 Apr; 16(4):500-5. PubMed ID: 27036356
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug discovery market exclusivity after KSR: the challenge to pharmaceutical scientists and the US congress.
    Wolff ME
    J Pharm Sci; 2011 Aug; 100(8):3044-3054. PubMed ID: 21472728
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.